子宫内膜异位症与子宫腺肌症的症状聚类及其对生活质量的影响:All of Us研究项目分析
子宫腺肌症集中于高疼痛类别且无最低症状组,高负担表型生活质量更差。
要点
- 子宫内膜异位症存在四种症状表型,包括高疼痛-胃肠道伴情绪症状及心理-神经主导型。
- 子宫腺肌症患者集中于高疼痛类别,无完全无症状组,整体疾病负担更高。
- 高负担表型与较差的总体健康、社会满意度降低及医疗可及性障碍增加相关。
核心结论
- 子宫内膜异位症和子宫腺肌症存在不同症状聚类,高负担表型患者生活质量更差。
研究设计与样本
- 对全队列及年龄校正亚组(18-45岁绝经前女性n=5542)等进行潜在类别分析,使用19种自报和电子健康记录来源的症状与合并症。
- 通过多项逻辑回归评估社会人口学和临床预测因素,并分析潜在类别与生活质量结局的关联。
主要发现
- 临床确诊子宫内膜异位症中识别出四种症状表型,包括严重的「高疼痛与胃肠道症状伴情绪症状」聚类和独特的「 predominantly 心理/神经」聚类。
- 子宫腺肌症患者呈现两个高疼痛症状类别,且无完全无症状组。
- 高疼痛类别与较低的总体健康评分、社会满意度降低及医疗可及性障碍增加显著相关。
临床怎么用
- 支持向个性化、跨学科管理转变,在盆腔痛之外关注心理健康和胃肠道症状。
- 对以非典型症状(焦虑、偏头痛、抑郁)就诊的年轻女性可考虑筛查子宫内膜异位症以减少诊断延迟。
局限性
- 研究基于美国人群,需在其他独立队列中验证普适性。
- 横断面设计限制了对生活质量结局的因果推断。
- 分析依赖手术和非手术临床诊断及自报诊断的混合,既是优势也是局限。
- 「最低症状负担」类别可能反映临床记录中症状记录不足而非真正无症状。
- 高症状类别可能反映合并症较多、就诊更频繁的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there distinct symptom clusters in women with endometriosis and adenomyosis, and how do these clusters predict quality of life? SUMMARY ANSWER: Latent class analyses of 22 438 women with endometriosis identified four symptom phenotypes, including high pain-gastrointestinal and psychological-neurological clusters; adenomyosis cases were concentrated in high‑pain classes without a minimal‑symptom group, and high‑burden phenotypes had poorer quality of life. WHAT IS KNOWN ALREADY: Endometriosis and adenomyosis are heterogeneous conditions with diagnostic delays of 4-11 years. The classification based on surgical findings and imaging fails to capture the complex, systemic symptom combinations that affect patients' quality of life (QoL). STUDY DESIGN, SIZE, DURATION: Large-scale cross-sectional cohort study using data from the United States-based All of Us Research Program (Controlled Tier v8; May 2018-October 2023). PARTICIPANTS/MATERIALS, SETTING, METHODS: The dataset included 22 438 women with electronic health records (EHR) and/or self-reported endometriosis. Four Latent Class Analyses (LCA) were performed on different patient groups: (i) the full endometriosis cohort (n = 22 438); (ii) an age-corrected subset restricted to premenopausal women (aged 18-45; n = 5542) to minimize menopausal confounding; and two subgroups derived from the age-corrected cohort to test whether concomitant adenomyosis defines distinct symptomatic phenotypes: (iii) clinically confirmed endometriosis without adenomyosis (n = 1797) and (iv) adenomyosis with endometriosis (n = 643). LCA was performed using 19 self-reported and EHR-derived symptoms and comorbidities (e.g. chronic pelvic pain, migraine, depression, gastrointestinal symptoms) to identify patient subgroups. Multinomial logistic regression assessed sociodemographic (age, BMI, deprivation index) and clinical predictors (hormonal contraceptive use, surgical history) of class membership. The association between latent classes and QoL outcomes was evaluated using data from the 'Overall Health' and 'Health Care Access and Utilization' surveys. Data are available via the All of Us Researcher Workbench (https://workbench.allofus.org). MAIN RESULTS AND THE ROLE OF CHANCE: Latent class analysis of clinically confirmed endometriosis identified four distinct symptom phenotypes, most notably a severe 'High Pain & Gastrointestinal with Mood Symptoms' (High) cluster and a unique 'Predominantly Psychological/Neurological' cluster that challenges traditional gynecological-focused diagnostic frameworks. Patients with adenomyosis exhibited a distinct profile with two high-pain symptom classes and the absence of a fully asymptomatic group, indicating a higher overall disease burden. Membership in the High class was significantly associated with lower general health scores, reduced social satisfaction, and increased barriers to healthcare access. LIMITATIONS, REASONS FOR CAUTION: The All of Us is a United States-based research program, and the findings should be replicated in other independent cohorts to confirm generalizability across other geographical regions. The cross-sectional design limits causal inference regarding QoL outcomes. Also, the analyses rely on a mix of diagnostic approaches, including surgical and non-surgical clinical and self-reported diagnoses, which is both a strength and a limitation. The 'Minimal Symptom Burden' class may reflect under-documentation of symptoms in clinical records rather than a true lack of symptoms, and the High class may reflect to patients who have higher multimorbidity, hence have more hospital visits. WIDER IMPLICATIONS OF THE FINDINGS: These results support a shift toward personalized, interdisciplinary management of endometriosis that addresses mental health and gastrointestinal symptoms alongside pelvic pain. The identification of a 'Predominantly Psychological/Neurological' cluster suggests that young women presenting with non-classical symptoms (anxiety, migraine, depression) could be screened for endometriosis to reduce diagnostic delays and improve life-course potential. FUNDING: D.K. was supported by a 'Ramón y Cajal' fellowship from the Spanish Ministry of Science and Innovation (RYC2024-050099-I). O.G. was supported by a postdoctoral award from the Amy P Goldman Foundation. DISCLOSURES: I.F. is the co-founder and co-owner of Sur180 Therapeutics, which is developing a novel treatment for endometriosis, and the Chief Scientific Officer of Nura Health, which is developing a non-invasive diagnostic solution for the disease. I.F. has received ARPA-H grant no. ARPA-H-ICHUB-24-101-1035 as Principal Investigator, consulting fees from Nura Health and Sur180 Therapeutics, and stock and share options in both companies. I.F. is also the inventor on patents for 'Compositions and methods for treating endometriosis' (US10695341 and US10729693) and serves as an unpaid Board Member of the World Endometriosis Society and the Fundación Puertorriqueña de Pacientes con Endometriosis (ENDOPR). H.S.T. received speaker fees from Gedeon Richter, a grant from AbbVie through Yale University, consulting fees from Regeneron, and is a co-inventor on Yale's endometriosis biomarkers and treatments (including US11993816B2, US10982282B2, and US12286629B2). He also serves on the boards of the Environmental Health Trust and Environment and Human Health. TRIAL REGISTRATION NUMBER: N/A.
引用
- Goroshchuk O, Pérez-Gómez N, Carmona F, et al. Characterizing endometriosis and adenomyosis symptom clusters and their impact on quality of life in the All of Us Research Program. Hum Reprod. 2026. PMID: 42381368. doi:10.1093/humrep/deag101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。